Sensei Biotherapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Operating expenses | $22.3M | $32.6M | $37.1M | $50.2M | $37.5M |
| Operating income | -$22.3M | -$32.6M | -$37.1M | -$50.2M | -$37.5M |
| Interest expense | $32,000 | $90,000 | $144,000 | $219,000 | $670,000 |
| Pretax income | -$21.1M | -$30.2M | — | — | — |
| Income tax expense | $0 | $0 | — | — | — |
| Net income | -$21.1M | -$30.2M | -$34.1M | -$48.6M | -$36.8M |
| Balance Sheet | |||||
| Cash and equivalents | $8.7M | $10.0M | $13.0M | $17.8M | $7.2M |
| Current assets | $21.5M | $41.9M | $67.2M | $108.6M | $148.5M |
| Total assets | $22.9M | $45.4M | $74.4M | $118.4M | $153.2M |
| Current liabilities | $4.3M | $5.4M | $5.6M | $9.1M | $4.9M |
| Total liabilities | $4.3M | $7.0M | $9.5M | $15.0M | $6.7M |
| Stockholders' equity | $18.6M | $38.4M | $64.9M | $103.4M | $146.5M |
| Cash Flow Statement | |||||
| Cash from operations | -$20.5M | -$24.7M | -$32.0M | -$39.0M | -$30.3M |
| Depreciation and amortization | $122,000 | $551,000 | $571,000 | $614,000 | $685,000 |
| Stock-based compensation | $1.3M | $3.1M | $4.5M | $5.8M | $5.7M |
| Capital expenditure | $16,000 | $146,000 | $180,000 | $321,000 | $2.0M |
| Free cash flow | -$20.5M | -$24.8M | -$32.2M | -$39.3M | -$32.3M |
| Share repurchases | — | — | $10.4M | — | — |
| Impairments | $0 | $951,000 | $0 | $0 | $0 |
Shares outstanding 1.3M
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.